Form 8-K - Current report:
SEC Accession No. 0001193125-25-051427
Filing Date
2025-03-11
Accepted
2025-03-11 07:04:16
Documents
17
Period of Report
2025-03-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d905827d8k.htm   iXBRL 8-K 50192
2 EX-2.1 d905827dex21.htm EX-2.1 686241
3 EX-99.1 d905827dex991.htm EX-99.1 43986
7 GRAPHIC g812767g0311064555055.jpg GRAPHIC 2806
8 GRAPHIC g905827dsp220.jpg GRAPHIC 3998
  Complete submission text file 0001193125-25-051427.txt   1113483

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tsvt-20250310.xsd EX-101.SCH 2877
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsvt-20250310_lab.xml EX-101.LAB 17978
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsvt-20250310_pre.xml EX-101.PRE 11276
19 EXTRACTED XBRL INSTANCE DOCUMENT d905827d8k_htm.xml XML 3625
Mailing Address 60 BINNEY STREET CAMBRIDGE MA 02210
Business Address 60 BINNEY STREET CAMBRIDGE MA 02210 339-499-9300
2seventy bio, Inc. (Filer) CIK: 0001860782 (see all company filings)

EIN.: 863658454 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40791 | Film No.: 25725827
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)